研究人员说, 液体活检可以在美国将晚期癌症诊断减少45%. Liquid biopsies could cut late-stage cancer diagnoses by 45% in the U.S., researchers say.

CANCER公布的一项新研究发现,常规的液体生物测试可以大大减少美国晚期癌症诊断。 通过模拟500万50至84岁成年人的年度多癌症早期检测,研究人员预测第四阶段癌症下降45%,早期检测增加。 A new study published in CANCER finds that routine liquid biopsy testing could significantly reduce late-stage cancer diagnoses in the U.S. By simulating annual multi-cancer early detection tests in 5 million adults aged 50 to 84, researchers projected a 45% drop in stage IV cancers, along with increases in early-stage detection. 肺癌、直肠癌和胰腺癌的减少幅度最大,而宫颈癌、肝癌和直肠癌的相对改善幅度最大。 The greatest reductions occurred in lung, colorectal, and pancreatic cancers, while cervical, liver, and colorectal cancers saw the largest relative improvements. 调查结果表明,这种检测可以通过更早地发现疾病、改善存活状况和降低治疗费用来改变癌症护理。 The findings suggest such tests could transform cancer care by catching disease earlier, improving survival, and lowering treatment costs.